130 related articles for article (PubMed ID: 19331127)
1. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
[TBL] [Abstract][Full Text] [Related]
3. Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.
Otsuka M; Mizuki M; Fujita J; Kang S; Kanakura Y
Anticancer Res; 2011 Jan; 31(1):113-22. PubMed ID: 21273588
[TBL] [Abstract][Full Text] [Related]
4. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
9. Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
Kim HJ; Kim SM; Park KR; Jang HJ; Na YS; Ahn KS; Kim SH; Ahn KS
Cancer Lett; 2011 Feb; 301(1):29-37. PubMed ID: 21122982
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
11. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
12. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
14. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
16. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
18. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
19. Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
Lee JC; Ahn KS; Jeong SJ; Jung JH; Kwon TR; Rhee YH; Kim SH; Kim SY; Yoon HJ; Zhu S; Chen CY; Kim SH
J Cell Biochem; 2011 Jun; 112(6):1552-62. PubMed ID: 21344490
[TBL] [Abstract][Full Text] [Related]
20. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
